
Release date: 2024-12-03 13:20:18 Article From: Lucius Laos Recommended: 267
Multiple myeloma is a relatively rare hematologic malignancy, and the dosage of ixazomib as an important drug for the treatment of this disease is very important for patients. This article will give you a detailed description of the dosage of ixazomib to help you better understand and use this medicine.
Ixazomib is an oral, highly selective proteasome inhibitor developed by Takeda Pharmaceutical. Since it was first approved for marketing in the United States in 2015, ixazomib has become one of the important drugs for the treatment of multiple myeloma.
In China, ixazomib has also been approved in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy.
The recommended starting dose of ixazomib is 4 mg orally once a week on days 1, 8 and 15 of a 28-day treatment cycle. Please note that patients should strictly follow the doctor's advice and take the medication at the prescribed dosage and time.
The combination of ixazomib is usually used in combination with lenalidomide and dexamethasone.
The recommended starting dose of lenalidomide is 25 mg once daily on days 1-21 of a 28-day treatment cycle. The recommended starting dose of dexamethasone is 40 mg on days 1, 8, 15, and 22 of a 28-day treatment cycle.
During the treatment process, the doctor will adjust the dose according to the patient's specific situation and the efficacy of the drug. If people experience adverse reactions or worsening conditions, doctors may reduce the dose of the drug or stop taking it. It is important for patients to follow their doctor's advice and not to adjust the dosage of the medication on their own.
Patients should follow their doctor's advice and take their medications on time and in the right amount. If you have any questions or discomfort, please consult your doctor promptly.
During the period of taking ixazomib, patients should pay close attention to their physical reactions, such as nausea, vomiting, diarrhea, fatigue and other adverse reactions, please inform the doctor in time. The doctor will deal with the patient accordingly according to the specific situation of the patient.
Patients should pay attention to dietary adjustment and avoid eating spicy, greasy and other irritating foods during the period of taking ixazomib, so as not to affect the efficacy of the drug. At the same time, patients should maintain good work and rest habits, and ensure adequate sleep and rest. As one of the important drugs for the treatment of multiple myeloma, the dosage of ixazomib is very important for patients. Patients should strictly follow their doctor's advice, take their medications on time and in the right amount, and monitor for adverse reactions. Through reasonable medication and dietary adjustment, it is believed that patients can overcome the disease and recover their health as soon as possible. If you have any questions or discomfort, please consult your doctor promptly.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643